TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2689345
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g i.v. bolus t.i.d. for a mean of 8.2 days)
Study: 31187152
Drug: IV THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV THC (0.05 mg/kg)
Study: 31187152
Drug: Tolcapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (200 mg) followed by IV THC
Study: 28594714
Drug: Standard radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiochemotherapy (Cap 50: 50 Gy irradiation and 1600 mg/m oral capecitabine daily) plus surgery (arm B)
Study: 21350408
Drug: Cytoflavin (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (infusion solution) prescribed in the first 2‐4 hours after delivery to 61 newborns
Study: 21350408
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (59 newborns who did not receive the drug)
Study: 17253066
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel (10cc)
Study: 17253066
Drug: Periprostatic lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periprostatic lidocaine injection (1% in 10cc)
Study: 14587264
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose given at least 6 hours before PCI
Study: 14587264
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily after PCI
Study: 14587264
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the loading dose of clopidogrel if intervention must be undertaken sooner
Study: 10893283
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus vinorelbine (G + V)
Study: 1579323
Drug: Cyclic treatment
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic treatment with 2 mg of estradiol valerate for 3 weeks + 250 micrograms of levonorgestrel for the last 10 days
Study: 1579323
Drug: 20-micrograms/24-hour levonorgestrel-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-micrograms/24-hour levonorgestrel-releasing intrauterine device (IUD) + 2 mg of estradiol valerate daily
Study: 1579323
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Cyclic treatment and IUD)
Study: 4044854
Drug: Non-treatment controls
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment controls (Institutionalized residents)
Study: 4044854
Drug: Non-treatment controls
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment controls (Staff counselors)
Study: 31854463
Drug: Shoulder block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoulder block (20 ml bupivacaine 0.5%)
Study: 31854463
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block (20 ml bupivacaine 0.5%)
Study: 24355241
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of hyaluronic acid (HA) using Ialumar® nasal spray for 30 days
Study: 24355241
Drug: Physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological solution (control group) for 30 days
Study: 21914589
Drug: Zonisamide (ZNS)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (ZNS) adjunctive therapy, dosage of 244.8 ± 108 mg/d at study end
Study: 21914589
Drug: Zonisamide (ZNS)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (ZNS) adjunctive therapy
Study: 14607015
Drug: Conventional paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional paracetamol tablets (1,500 mg) with morphine (10 mg 4 hourly for 12 hours prior)
Study: 14607015
Drug: Conventional paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional paracetamol tablets (1,500 mg) without morphine
Study: 14607015
Drug: Dispersible paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible paracetamol tablets (1,500 mg) with morphine (10 mg 4 hourly for 12 hours prior)
Study: 14607015
Drug: Dispersible paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible paracetamol tablets (1,500 mg) without morphine
Study: 11004039
Drug: 1% hypobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% hypobaric lidocaine 50 mg (Group L50)
Study: 11004039
Drug: 1% hypobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% hypobaric lidocaine 20 mg + 25 microg fentanyl (Group L20/F25)
Study: 31733786
Drug: Treadmill gait
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill gait training together with traditional treatment
Study: 27495291
Drug: Glimepiride (6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (6-8 mg)
Study: 27600862
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg and 300 mg)
Study: 20132586
Drug: Oil diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil diet (mean beta-carotene intake 3.1 mg/d)
Study: 20132586
Drug: Mixed diet
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed diet (mean beta-carotene intake 7.6 mg/d)
Study: 17714824
Drug: Repaglinide/Metformin/NPH (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide/Metformin/NPH (Group A)
Study: 17714824
Drug: Metformin/NPH (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/NPH (Group B)
Study: 11967679
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenous before extubation
Study: 371319
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic bowel preparation for 24 hours
Study: 371319
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic bowel preparation for 60 hours
Study: 371319
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic bowel preparation (both 24 and 60 hours)
Study: 31609189
Drug: Long-acting injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injection formulations of SGAs
Study: 30400965
Drug: Opioid replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid replacement therapy
Study: 24029470
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment (control)
Study: 14500162
Drug: Ropivacaine 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 3.75 mg/mL
Study: 12191848
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 microg daily for 12 months
Study: 12191848
Drug: Transdermal norethisterone
Normalized name: ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal norethisterone acetate (NETA) continuously (170 or 350 microg/day)
Study: 12191848
Drug: Sequential oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential oral NETA (1 mg/day)
Study: 12191848
Drug: Dydrogesterone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (20 mg/day)
Study: 3428285
Drug: Carbimazole pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole pretreatment for a minimum of three months before 131I therapy
Study: 3428285
Drug: 131I therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I therapy alone
Study: 29121294
Drug: Buprenorphine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine i.v. infusion (25 μg h ‐1 for 24 h)
Study: 29121294
Drug: Morphine (equianalgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (equianalgesic dose)
Study: 25637938
Drug: bupivacaine, 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine, 0.25% 30 mL
Study: 25637938
Drug: bupivacaine, 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine, 0.25% 30 mL with 1‐mg dexamethasone
Study: 25637938
Drug: bupivacaine, 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine, 0.25% 30 mL with 2‐mg dexamethasone
Study: 25637938
Drug: bupivacaine, 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine, 0.25% 30 mL with 4‐mg dexamethasone
Study: 25637938
Drug: dexamethasone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone (all doses)
Study: 23948110
Drug: Drug eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug eluting stent (DES)
Study: 16458131
Drug: Upstream use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upstream use of small molecule GP IIb/IIIa inhibitors for all ACS patients
Study: 12758236
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus mitomycin C (MMC) (15 mg/m² single injection at the end of the first week of radiotherapy)
Study: 10739392
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg aspirin/day p.o. for 11 days
Study: 10739392
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin/day p.o. for 11 days
Study: 10739392
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg L-aspirin infusion
Study: 8157945
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg for the first month, 20 mg for the second month, 40 mg for the remaining 4 months)
Study: 3063660
Drug: Penfluridol, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol, administered once weekly
Study: 3063660
Drug: Trifluoperazine, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluoperazine, administered twice daily
Study: 28120856
Drug: l-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine supplementation (2 g per day)
Study: 24589310
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose MDCT
Study: 24589310
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose MDCT
Study: 20211294
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 81 to 324 mg once daily
Study: 15298986
Drug: Unilateral Limb
Normalized name: BANDAGE TUBULAR ELAST TUBIFAST LG LIMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral Limb Suspension (ULLS)
Study: 9659857
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day of olanzapine
Study: 9659857
Drug: 1200 mg/day
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/day of chlorpromazine plus 4 mg/day of benztropine mesylate
Study: 2500466
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment of 40 weekly sessions
Study: 2500466
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of 20 weekly sessions
Study: 31226526
Drug: Citric acid/tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citric acid/tetracycline gel (CAT) group
Study: 25684586
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 μg orally once daily
Study: 21700430
Drug: Iloperidone 10-16
Normalized name: iloperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone 10-16 mg
Study: 21700430
Drug: Iloperidone 20-24
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 20-24 mg
Study: 16701187
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL bupivacaine plus midazolam 2 mg
Study: 16701187
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL bupivacaine plus midazolam 1 mg
Study: 16701187
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL hyperbaric bupivacaine 0.5%
Study: 11092646
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg (combined with medroxyprogesterone acetate 2.5 mg daily in five women with uterus intact)
Study: 9126089
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in the 20 mg group)
Study: 1530172
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lidocaine + 0.05 mg of fentanyl + 0.5 mg of pancuronium (group D)
Study: 1530172
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lidocaine + 0.05 mg of fentanyl (group B)
Study: 1530172
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lidocaine + 0.5 mg of pancuronium (group C)
Study: 1530172
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lidocaine (group A)
Study: 1530172
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lidocaine + 0.05 mg of fentanyl + 0.5 mg of pancuronium (group E) for safety evaluation
Study: 27160164
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (twice a week for 12 months)
Study: 22119927
Drug: Pentavac(®) vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavac(®) vaccine manufactured at large scale
Study: 22119927
Drug: Pentavac(®) vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavac(®) vaccine manufactured at small scale
Study: 20580361
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 20 mg vaginally
Study: 19205545
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus placebo
Study: 10352617
Drug: NC100150 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC100150 injection with respiratory gating
Study: 9082765
Drug: Intranasal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunization with P6 (twice, with 2 weeks in between)
Study: 9082765
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of rIL-2 and rIL-5
Study: 1937985
Drug: gallopamil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil (50 mg thrice daily)
Study: 1937985
Drug: diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem (60 mg thrice daily)
Study: 6128086
Drug: Pirbuterol (PB)
DrugBank: Pirbuterol (DB01291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirbuterol (PB) 20 mg three times daily
Study: 6128086
Drug: Pirbuterol (PB)
DrugBank: Pirbuterol (DB01291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirbuterol (PB) 20 mg and 30 mg doses
Study: 28844499
Drug: Rindopepimut (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rindopepimut (500 μg admixed with 150 μg GM‐CSF) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Study: 28844499
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 μg keyhole limpet haemocyanin) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Study: 19269731
Drug: No chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chlorhexidine treatment (Control)
Study: 17381964
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 3.9 g/d
Study: 15200656
Drug: Rofecoxib 1
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 1 mg x kg(‐1) (max 25 mg)
Study: 8387191
Drug: Nedocromil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil (4 x 4 mg/d)
Study: 3440107
Drug: Rectally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectally administered carbamazepine mixture
Study: 3440107
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered carbamazepine mixture
Study: 31888762
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega-3 fatty acid twice a day + vitamin D placebo every two weeks
Study: 31888762
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid placebo twice a day + 50,000 IU vitamin D every two weeks
Study: 31888762
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega-3 fatty acid twice a day + 50,000 IU vitamin D every two weeks
Study: 31888762
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid placebo twice a day + vitamin D placebo every two weeks
Study: 20072045
Drug: HMB +
Normalized name: Hydroxymethylbutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB + KIC (3 g.d HMB and 0.3 g.d KIC)
Study: 20072045
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g.d corn flour)
Study: 17492341
Drug: Partly absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partly absorbable polypropylene-polyglactin mesh (Vypro II(R) 50 g/m(2), 79 hernias)
Study: 17492341
Drug: Lightweight polypropylene
Normalized name: polypropylene (30000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lightweight polypropylene mesh (Premilene Mesh LP(R) 55 g/m(2), 75 hernias)
Study: 17492341
Drug: Conventional densely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional densely woven polypropylene mesh (Premilene(R) 82 g/m(2), 78 hernias)
Study: 8681919
Drug: No‐treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No‐treatment control condition
Study: 2194652
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of methotrexate and teniposide
Study: 2194652
Drug: Sequential infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential infusion of methotrexate followed by teniposide
Study: 26053503
Drug: Hydrophobic chlorhexidine‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophobic chlorhexidine‐based gingiva‐adhering gel (applied once every second day for 14 days)
Study: 26053503
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine water‐soluble gel (applied twice daily)
Study: 16030082
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural corticosteroid injections (ESI) of triamcinolone acetonide, administered three times at intervals of 3 weeks.
Study: 16030082
Drug: Interligamentous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interligamentous saline injections (placebo control), administered three times at intervals of 3 weeks.
Study: 12042368
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg kg(‐1))
Study: 31564317
Drug: Latanoprost administration
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost administration
Study: 31564317
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of latanoprost
Study: 23808222
Drug: Preoperative photodynamic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative photodynamic therapy (PhT) using chlorine E6 and light of wavelength 662 nm
Study: 23808222
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without photodynamic therapy (PhT)
Study: 23808222
Drug: Preoperative photodynamic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative photodynamic therapy (PhT)
Study: 21920260
Drug: Biodegradable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable polymer drug-eluting stents (n = 1,299)
Study: 21920260
Drug: Permanent polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent polymer drug-eluting stents (n = 1,304)
Study: 12177646
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy with > or =5 shocks
Study: 9952095
Drug: Caffeine sodium
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine sodium benzoate (500 mg) in 1,000 mL normal saline
Study: 9952095
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) in 1,000 mL
Study: 2259226
Drug: DA (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA (daunorubicin 45 mg/m2/day x 3)
Study: 2259226
Drug: MA (m-AMSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA (m-AMSA 200 mg/m2/day x 3 days)
Study: 7402449
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg naloxone
Study: 28192477
Drug: Early pharmacist-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early pharmacist-led medication review
Study: 28192477
Drug: Early pharmacist-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early pharmacist-led medication review (for patients under 80 years)
Study: 26486192
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo)